After a week of intense haggling, the World Health Assembly has adopted a controversial resolution designed to improve access to medicines. Yet the effort received decidedly mixed reviews over language that bolstered transparency into drug pricing, but maintained a curtain around key R&D costs.
The resolution, which was introduced last February by Italy and co-sponsored by 20 other countries, is seen as a vehicle by cash-strapped governments to control their drug spending, an issue that has reverberated around the world and, increasingly, engulfed wealthy nations, as well.
About the Author Reprints
